207 related articles for article (PubMed ID: 20958109)
1. To switch (statins) or not to switch? That is the question.
Athyros VG; Tziomalos K; Karagiannis A; Mikhailidis DP
Expert Opin Pharmacother; 2010 Dec; 11(18):2943-6. PubMed ID: 20958109
[TBL] [Abstract][Full Text] [Related]
2. When choosing statin therapy: the case for generics.
Green JB; Ross JS; Jackevicius CA; Shah ND; Krumholz HM
JAMA Intern Med; 2013 Feb; 173(3):229-32. PubMed ID: 23303273
[TBL] [Abstract][Full Text] [Related]
3. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Tran YB; Frial T; Miller PS
Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
5. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence.
Kaló Z; Muszbek N; Bodrogi J; Bidló J
Health Policy; 2007 Mar; 80(3):402-12. PubMed ID: 16730848
[TBL] [Abstract][Full Text] [Related]
6. The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices.
Plans-Rubió P
Am J Cardiovasc Drugs; 2010; 10(6):369-82. PubMed ID: 21090830
[TBL] [Abstract][Full Text] [Related]
7. Cost efficiency and formulary considerations for statin therapy.
Killilea T; Funk L
Am J Manag Care; 2006 Oct; 12(11 Suppl):S325-31. PubMed ID: 17042675
[TBL] [Abstract][Full Text] [Related]
8. Clinical review: impact of statin substitution policies on patient outcomes.
Atar D; Carmena R; Clemmensen P; K-Laflamme A; Wassmann S; Lansberg P; Hobbs R
Ann Med; 2009; 41(4):242-56. PubMed ID: 19191052
[TBL] [Abstract][Full Text] [Related]
9. Better outcomes with generic statins.
Harv Heart Lett; 2014 Dec; 25(4):8. PubMed ID: 26094262
[No Abstract] [Full Text] [Related]
10. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
Robinson JG
Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Hirsch M; O'Donnell JC; Jones P
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
[TBL] [Abstract][Full Text] [Related]
12. Effects of direct-to-consumer advertising of hydroxymethylglutaryl coenzyme a reductase inhibitors on attainment of LDL-C goals.
Bradford WD; Kleit AN; Nietert PJ; Ornstein S
Clin Ther; 2006 Dec; 28(12):2105-18; discussion 2104. PubMed ID: 17296467
[TBL] [Abstract][Full Text] [Related]
13. Newer, lower, better? Lipid drugs and cardiovascular disease--the continuing story.
Wierzbicki AS
Int J Clin Pract; 2007 Jul; 61(7):1064-7. PubMed ID: 17577288
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden.
Martikainen JA; Soini E; Paulsson T
Curr Med Res Opin; 2010 Feb; 26(2):389-96. PubMed ID: 20001451
[TBL] [Abstract][Full Text] [Related]
15. High-dose statin therapy: benefits and safety in aggressive lipid lowering.
Toth PP; Davidson MH
J Fam Pract; 2008 May; 57(5 Suppl High-Dose):S29-36. PubMed ID: 18662521
[No Abstract] [Full Text] [Related]
16. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin.
Hess G; Sanders KN; Hill J; Liu LZ
Am J Manag Care; 2007 Jun; 13 Suppl 3():S80-5. PubMed ID: 17596116
[TBL] [Abstract][Full Text] [Related]
17. Statin utilisation--recognising the role of the invisible hand.
Minhas R
Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171
[No Abstract] [Full Text] [Related]
18. The paradigm of stains: will the lower cost of generics translate into health gains?
Seabra-Gomes R
Rev Port Cardiol; 2007 May; 26(5):497-501. PubMed ID: 17691276
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
[TBL] [Abstract][Full Text] [Related]
20. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
Moyad MA; Merrick GS
Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
